
Colonial ideas of beauty: how skin lightening products are linked to cancer in black African women
The anonymous patient, from Togo, is one of a string of recent cases reported in medical journals of cancers in black African women linked to skin-lightening creams and lotions, prompting dermatologists to call for better regulation.
The melanin found in darker skin typically offers some protection against the sun damage which can cause cancers.
'Patients with black skin have a natural SPF of about 15, just by having pigmented skin,' says Prof Ncoza Dlova, head of dermatology at the University of KwaZulu-Natal, South Africa,. 'If they remove that melanin [with skin lightening creams], they're actually removing the natural protection.'
Estimates of skin lightening product use in African countries range from 25% to 80% of women. Lighter skin is often seen as more desirable, in a trend with complex drivers including values imported in the colonial era.
Dlova and colleagues are writing up a paper citing more than 55 cancer cases, from countries including Mali and Senegal.
'If we are getting self-induced skin cancer, then that's a red flag and worrying,' says Dlova. 'We have to do something about it.'
The market for skin lightening product is growing, with analysts predicting that the current market size of US$10.7bn (£8bn) will reach US$18.1bn by 2033. There are even reports of the products being used on babies and young children.
For Dlova, they are 'a health hazard that needs to be addressed'. Almost every day, she says, her clinic in Durban will see someone with a skin problem linked to lightening products. 'Of course, not all of them are coming with skin cancer … They come in with fungal infections that are resistant to the common treatment that we normally use. They present with pimples, referred to as steroid-induced acne, as well as rosacea. Some present with permanent stretch marks; all these complications are extremely common.'
The Togo patient had three large, painful, cancerous tumours on her neck, which she had tried to treat with antibiotics, antiseptics and traditional herbal poultices with no success before going to hospital. One of the tumours was removed, but the others were too close to blood vessels and she could not afford the recommended chemotherapy.
She told her doctors she had used creams that included topical hydroquinone and highly potent corticosteroids for about 30 years.
In another series of eight cancers, reported in Senegal, the women had used similar products for about 20 years on average. Two of those patients died.
Hydroquinone as a skin lightener has been banned in South Africa since 1990, and other African countries including Rwanda, Ivory Coast, Tanzania, Kenya, and Ghana followed suit. Those bans were prompted by serious concerns about an irreversible form of skin damage called ochronosis.
But regulation is often weak, and the products are reportedly still available from street vendors and cosmetic shops.
The use of steroids in skin lighteners is a newer phenomenon. Topical steroids are used in dermatology to treat inflammatory skin conditions such as eczema, but a side-effect is that they make skin lighter, a fact exploited for their use in cosmetics.
If the two problematic ingredients are used together they can have a 'synergistic effect', Dlova says.
The International League of Dermatological Societies (ILDS) has published an alert warning about the dangers of misuse of potent topical steroids, and is calling for governments to better regulate the products. The problem goes beyond Africa, says the ILDS president Prof Henry Lim, with the problem first raised by its members in India.
After South Africa's hydroquinone ban, there was a lull in how frequently dermatologists encountered complications of skin bleaching, Dlova says 'but again, in the last 10 years there was just a sudden eruption of the complications of skin bleaching again. Skin cancer per se had not been described before, it's only been described recently. So obviously, things have got worse – because from irreversible pigmentation [ochronosis] to skin cancer, those are really red flags implying that we need to do something about it.'
While the desire for lighter skin is not new, Dlova suspects the rise of social media over the past decade has led to increased use, pointing to smartphone filters that make skin look smoother and lighter.
Tackling the issue will require action from many sectors – not only regulatory agencies.
'Marketing, social media and media all have a role to play – fashion, celebrities and all of that. If they use black models who are lighter in skin colour, the message they are conveying is that you are prettier, you can be a model, you are more attractive if you are lighter. So we need to ensure that the advertisements include diverse skin colours when they are choosing their models,' says Dlova.
She also wants to see skin health education in preschools to teach children to be proud of their natural skin, and to get across the message of using sunscreen.
Some black patients will have skin challenges including pigmentation disorders, she says, which may require creams with lightening ingredients. But these should be used under medical supervision.
Part of the ILDS advocacy will be asking pharmaceutical companies to make those prescription products more affordable, so that people do not need to turn to cheaper off-the-shelf products that may be dangerous.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
6 hours ago
- Daily Mail
Horror as 'Frankenstein' drug that's FORTY TIMES stronger than fentanyl wreaks havoc across the US... and kids are buying it on their phones
Doctors and law enforcement are warning of a deadly surge in a so-called 'Frankenstein' opioid 40 times stronger than fentanyl that could wreak havoc across America. Nitazenes, a class of synthetic drugs pouring in from China, are up to 2,000 times more potent than heroin, meaning that a tiny dose can kill.


Daily Mail
21 hours ago
- Daily Mail
New study shows using marijuana triples risk of developing cancer
People who frequently use marijuana more than triple their risk of developing oral cancer , a new study found. About half of US adults say they have ever tried marijuana, with about 17.7million suffering from symptoms of cannabis use disorder (CUD) . The condition requires a formal diagnosis after fulfilling several criteria, such as using the drug despite the negative impacts it has on a person's life and relationships. University of California , San Diego researchers followed 45,000 people, some with cannabis use disorder, for five years. They discovered that daily smokers were 3.25 times more likely to develop oral cancer than those without the disorder. Dr Raphael Cuomo, an anesthesiology professor at UC San Diego School of Medicine who led the analysis, said: 'Cannabis smoke contains many of the same carcinogenic compounds found in tobacco smoke, which have known damaging effects on the epithelial tissue that lines the mouth.' Cannabis smoke packs a heavy load of toxic chemicals and carcinogens, about 2,600 of them, similar to tobacco smoke. But researchers are only recently getting a fuller understanding of what those chemicals are. They now know that marijuana smoke contains hundreds of polycyclic aromatic hydrocarbons (PAHs), benzene, and ammonia. These chemicals adhere to mucus membranes in the mouth, enabling carcinogens to seep into oral tissue. Meanwhile, THC, the psychoactive chemical in marijuana, can suppress crucial immune system pathways that would typically patrol for, and kill, those rogue cells. Of the more than 45,000 patients included in the study, 949 had cannabis use disorder. The group that did not smoke or smoked only occasionally remained either weed free or only occasional users over the five-year study. Over 97 percent were still abstinent or infrequent users by the time researchers followed up. During the study, 106 patients were diagnosed with oral cancer. Among people without CUD, the rate of oral cancer was 0.23 percent, which matches general population rates. However, among participants with CUD, 0.74 percent developed oral cancer. Oral cancer includes cancerous growths that develop in the mouth and throat, including the lips, tongue, gums, the floor of the mouth and the roof of the mouth. About one in 59 men and 1 in 139 women will develop oral cancer at some point in their lives. Oral cancers account for about three percent of cancers diagnosed in the US every year, with about 58,500 diagnoses and 12,250 deaths annually. Researchers said their findings will have implications for cancer screening practices in primary care and mental health settings, as patients with CUD often present with overlapping social and behavioral risk factors, including tobacco use, alcohol use, and a lower likelihood of engaging in preventive healthcare. People with CUD who were also tobacco users were 6.24 times more likely to get oral cancer. Age also played a role, with each additional year of age increasing cancer risk by about four times per year. Like tobacco smokers, marijuana smokers see damage to their lung and throat cells, leading to abnormal cell growth that can cause cancer and tissue changes. Those effects can occur in people who are not tobacco smokers, though, indicating that marijuana smoke can be just as harmful on its own as cigarette smoke. Dr Cuomo said: 'These findings add to a growing body of evidence suggesting that chronic or problematic cannabis use may contribute to cancer risk in tissues exposed to combustion products.' Their findings were published in the journal Preventive Medicine Reports . In the United States, marijuana is fully legal for recreational and medicinal use in 29 states. It is entirely illegal in four states. The majority of the public, about 88 percent , supports legalization, according to the Pew Research Center. But public health experts are raising concerns over potential long-term effects, of which scientists still do not have a complete understanding. In June, University of California researchers reviewed 24 studies involving 200million people to investigate the relationship between weed and cardiovascular disease, stroke and acute coronary syndrome (ACS) - a group of heart conditions in which there is reduced or blocked blood flow to the heart, such as a heart attack. They found there was a 29 percent higher risk of ACS among cannabis users, a 20 percent higher risk for stroke and double the risk of dying from cardiovascular disease, which includes coronary artery disease, heart failure and irregular heartbeats. Last month, findings from an FDA-run clinical trial were released, investigating dangerous liver enzyme spikes in people who consumed cannabis. The results showed that eight users of CBD, the substance derived from the hemp plant that's free of the psychoactive chemical THC, developed enzyme spikes above the safe threshold, raising the risk of chronic liver damage or failure. Seven people dropped out due to liver concerns between weeks three and four. However, everyone's liver tests normalized after quitting CBD. Meanwhile, regular use of potent cannabis in adolescence has been linked to long-term changes in brain structure, particularly in the prefrontal cortex, the region responsible for decision-making, emotional regulation, and impulse control. This is also the age when many psychotic disorders first appear. THC may trigger schizophrenia or psychotic episodes in individuals with genetic predispositions. A 2022 review by University of Bath researchers, which analyzed 20 studies involving 120,000 people, found users of high-potency cannabis were four times more likely to develop addiction and three to five times more likely to suffer a psychotic break compared to those using lower-potency strains. Earlier this year, a report in JAMA Network Open found that emergency room visits in Ontario, Canada, linked to schizophrenia in marijuana users tripled after legalization. Between 2006 and 2022, the rate of schizophrenia among those with cannabis use disorder climbed from four percent to over 10 percent. In contrast, just 0.6 percent of non-users developed the condition.


Daily Mail
21 hours ago
- Daily Mail
Dirty habit followed by 18million Americans TRIPLES the risk of getting cancer
People who frequently use marijuana more than triple their risk of developing oral cancer, a new study found. About half of US adults say they have ever tried marijuana, with about 17.7million suffering from symptoms of cannabis use disorder (CUD). The condition requires a formal diagnosis after fulfilling several criteria, such as using the drug despite the negative impacts it has on a person's life and relationships. University of California, San Diego researchers followed 45,000 people, some with cannabis use disorder, for five years. They discovered that daily smokers were 3.25 times more likely to develop oral cancer than those without the disorder. Dr Raphael Cuomo, an anesthesiology professor at UC San Diego School of Medicine who led the analysis, said: 'Cannabis smoke contains many of the same carcinogenic compounds found in tobacco smoke, which have known damaging effects on the epithelial tissue that lines the mouth.' Cannabis smoke packs a heavy load of toxic chemicals and carcinogens, about 2,600 of them, similar to tobacco smoke. But researchers are only recently getting a fuller understanding of what those chemicals are. They now know that marijuana smoke contains hundreds of polycyclic aromatic hydrocarbons (PAHs), benzene, and ammonia. These chemicals adhere to mucus membranes in the mouth, enabling carcinogens to seep into oral tissue. Meanwhile, THC, the psychoactive chemical in marijuana, can suppress crucial immune system pathways that would typically patrol for, and kill, those rogue cells. Of the more than 45,000 patients included in the study, 949 had cannabis use disorder. The group that did not smoke or smoked only occasionally remained either weed free or only occasional users over the five-year study. Over 97 percent were still abstinent or infrequent users by the time researchers followed up. During the study, 106 patients were diagnosed with oral cancer. Among people without CUD, the rate of oral cancer was 0.23 percent, which matches general population rates. However, among participants with CUD, 0.74 percent developed oral cancer. Oral cancer includes cancerous growths that develop in the mouth and throat, including the lips, tongue, gums, the floor of the mouth and the roof of the mouth. About one in 59 men and 1 in 139 women will develop oral cancer at some point in their lives. Oral cancers account for about three percent of cancers diagnosed in the US every year, with about 58,500 diagnoses and 12,250 deaths annually. Researchers said their findings will have implications for cancer screening practices in primary care and mental health settings, as patients with CUD often present with overlapping social and behavioral risk factors, including tobacco use, alcohol use, and a lower likelihood of engaging in preventive healthcare. People with CUD who were also tobacco users were 6.24 times more likely to get oral cancer. Age also played a role, with each additional year of age increasing cancer risk by about four times per year. Like tobacco smokers, marijuana smokers see damage to their lung and throat cells, leading to abnormal cell growth that can cause cancer and tissue changes. Those effects can occur in people who are not tobacco smokers, though, indicating that marijuana smoke can be just as harmful on its own as cigarette smoke. Dr Cuomo said: 'These findings add to a growing body of evidence suggesting that chronic or problematic cannabis use may contribute to cancer risk in tissues exposed to combustion products.' Their findings were published in the journal Preventive Medicine Reports. In the United States, marijuana is fully legal for recreational and medicinal use in 29 states. It is entirely illegal in four states. The majority of the public, about 88 percent, supports legalization, according to the Pew Research Center. But public health experts are raising concerns over potential long-term effects, of which scientists still do not have a complete understanding. In June, University of California researchers reviewed 24 studies involving 200million people to investigate the relationship between weed and cardiovascular disease, stroke and acute coronary syndrome (ACS) - a group of heart conditions in which there is reduced or blocked blood flow to the heart, such as a heart attack. They found there was a 29 percent higher risk of ACS among cannabis users, a 20 percent higher risk for stroke and double the risk of dying from cardiovascular disease, which includes coronary artery disease, heart failure and irregular heartbeats. Last month, findings from an FDA-run clinical trial were released, investigating dangerous liver enzyme spikes in people who consumed cannabis. The results showed that eight users of CBD, the substance derived from the hemp plant that's free of the psychoactive chemical THC, developed enzyme spikes above the safe threshold, raising the risk of chronic liver damage or failure. Seven people dropped out due to liver concerns between weeks three and four. However, everyone's liver tests normalized after quitting CBD. Meanwhile, regular use of potent cannabis in adolescence has been linked to long-term changes in brain structure, particularly in the prefrontal cortex, the region responsible for decision-making, emotional regulation, and impulse control. This is also the age when many psychotic disorders first appear. THC may trigger schizophrenia or psychotic episodes in individuals with genetic predispositions. A 2022 review by University of Bath researchers, which analyzed 20 studies involving 120,000 people, found users of high-potency cannabis were four times more likely to develop addiction and three to five times more likely to suffer a psychotic break compared to those using lower-potency strains. Earlier this year, a report in JAMA Network Open found that emergency room visits in Ontario, Canada, linked to schizophrenia in marijuana users tripled after legalization. Between 2006 and 2022, the rate of schizophrenia among those with cannabis use disorder climbed from four percent to over 10 percent. In contrast, just 0.6 percent of non-users developed the condition.